Print

BioMarin Pharmaceutical Inc. (BMRN) Release: FDA Accepts Vimizim BLA and Grants Priority Review Designation  
5/30/2013 9:44:05 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

SAN RAFAEL, Calif., May 30, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for Vimizim (BMN-110, elosulfase alfa), an enzyme replacement therapy under evaluation for the treatment of patients with the rare lysosomal storage disorder Mucopolysaccharidosis Type IVA (MPS IVA), also called Morquio A Syndrome.

Help employers find you! Check out all the jobs and post your resume.

//-->